Acquired Company

Inmagene Biopharmaceuticals completed its merger with Ikena Oncology on 7/25/2025, and the combined company will trade on Nasdaq under the ticker IMA.

Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd. Show more

645 Summer Street, Boston, MA, 02210, United States

https://ikenaoncology.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

718.8M

52 Wk Range

$1.36 - $23.28

Previous Close

$7.00

Open

$7.10

Volume

12,524

Day Range

$6.51 - $7.18

Enterprise Value

628.9M

Cash

95.64M

Avg Qtr Burn

-7.296M

Insider Ownership

8.00%

Institutional Own.

76.21%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IK-175 (AHR Inhibitor) Details Bladder cancer, Solid tumor/s, Cancer, Urothelial carcinoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-595 (MEK-RAF Molecular Glue) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-930 (TEAD1) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.